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THE FIRST AMENDMENT: NOT ONE SIZE FITS ALL
Caroline Poplin
INTRODUCTION
In the last twenty years or so, the Republican conservatives on the U.S.
Supreme Court have relished overturning settled constitutional doctrine,
particularly to benefit corporations at the expense of their customers, workers,
investors, and ordinary people in general. The First Amendment has been one
of their favorite tools.
The poster case for this successful effort is, of course, Citizens United,
where the court majority overturned restrictions on corporate campaign
contributions that had stood for almost a century.1
Less well known, but still important, the Court has challenged the
traditional restriction of First Amendment protection to political speech, and
extended constitutional protection to “commercial speech”, speech—such as
advertising—by a business to promote a product to make money. 2 Or maybe
the product itself is speech, or data. Speech is speech, the Court seems to say,
and as long as it is truthful and not misleading, maybe there are people who
want to listen and learn. The Supreme Court case is Sorrel v. IMS Health 131
S. Ct. 2653 (2011).

 Dr. Caroline Poplin is an attorney and a physician. She graduated from Yale Law School and practiced
law for a dozen years at FDA, EPA, and Mayer Brown. She received her medical degree from the University
of Rochester School of Medicine, and completed a residency in Internal Medicine at Georgetown University
Hospital. Subsequently, she practiced inpatient and outpatient medicine for the Department of Defense,
retiring from Bethesda Naval Hospital in 2007. She spent a year as a Visiting Scholar at Georgetown
University Law Center, and another as a Visiting Fellow at the Center for American Progress. She currently
serves as Of Counsel and Medical Director at Guttman, Buschner and Brooks LLP. She has worked on half a
dozen high-profile cases of Medicare and Medicad fraud, including off-label marketing cases against Abbott,
GlaxoSmithKine, Amgen, and Wyeth, Anti-Kickback Statute cases against Pharmerica and Omnicare, as well
as fraud at Community Health Services (a national hospital chain). She currently practices medicine at the
Arlington Free Clinic, and has published articles in academic journals, more than a dozen op-eds in national
newspapers, and articles on the Health Affairs blog. She is presently a columnist with Medpage, a medical
newsletter.
1 Citizens United v. Fed. Election Comm’n, 558 U.S. 310, 318–19 (2010).
2 Sorrel v. IMS Health, 131 S. Ct. 2653, 2672–74, 2677 (2011).
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In 2010, the Second Circuit went the Supreme Court one better, in United
States v. Caronia, 703 F.3d 149 (2nd Cir. 2012).3 The case involved a
pharmaceutical salesman, Alfred Caronia, who promoted Xyrem, a drug
approved by the Federal Drug Administration (FDA) only for cataplexy in
narcolepsy, and excessive daytime sleepiness in narcolepsy.4 Caronia was
recorded telling a physician that Xyrem could be used for insomnia,
fibromyalgia [a common but not well-understood pain syndrome], Parkinson’s
disease, chronic fatigue, obesity and other common problems.5 Also that
neurologists use it for children between eight and ten, and patients over 65.6
“It’s a very safe drug,” said Mr. Caronia.7 The FDA prosecuted the salesman
for “misbranding”, the conviction was upheld by the District Court, and
overturned by the Second Circuit.8
Speech, written or other material promoting a drug for a use not approved
by the FDA, has always been considered good evidence of “misbranding,” so
prohibited by the Food, Drug and Cosmetic Act (FDCA).9 As “commercial
speech,” such promotion had never been entitled to any special protection:
large pharmaceutical companies have paid billions of dollars in fines in recent
years to settle Federal government allegations of misbranding evidenced by
off-label marketing.10 Nevertheless, in Caronia the Second Circuit held that
the drug representative’s promotion of off-label uses of Xyrem was now
protected by the First Amendment as long as it was “truthful and not
misleading”.11
In August 2015, a judge in the Southern District of New York, following
what he called “[the] modern First Amendment law” as set out by the Second
Circuit in Caronia, upheld pharmaceutical manufacturer Amarin’s
constitutional right to promote its drug, Vascepta, for an off-label use,12 since it

3

United States v. Caronia, 703 F.3d 149 (2nd Cir. 2012).
Id. at 152, 155.
5 Id. at 157, 171.
6 Id. at 157.
7 Id. at 156–57.
8 Id. at 152.
9 See generally, 21 U.S.C. § 331 (2012) (stating that the adulteration or misbranding of any food, drug,
device, tobacco product, or cosmetic in interstate commerce is prohibited).
10 See Lena Groeger, Big Pharma’s Big Fines, PROPUBLICA (Feb. 24, 2014), http://projects.propublica.
org/graphics/bigpharma.
11 Caronia, 703 F.3d at 175.
12 Amarin Pharma Inc. v. U.S. Food and Drug Admin., No. 15-03588, 2015 U.S. Dist. LEXIS 103944, at
*80 (S.D.N.Y. 2015).
4
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found that Amarin’s message was “truthful and non-misleading.”13 Judge
Engelmeyer noted in passing how common—and important—off-label use of
drugs is: “And the therapeutic—indeed, sometimes life-saving—value of offlabel uses of FDA approved drugs has been widely recognized”.14 He
apparently finds this sweeping proposition so intuitively obvious he offers no
support for it.
One more point to keep in mind. Congress, the FDA and Department of
Justice (DOJ) have always been clear that nothing in the FDCA, from its
original passage in 1906 to the present day, constrains in any way a licensed
physician’s right and responsibility to prescribe any drug legitimately on the
market for any condition he or she thinks appropriate.15 The Second Circuit
uses this, though, as an argument to support off-label marketing—it helps
‘educate’ the physicians.16
Nevertheless, these decisions have caused great consternation in the
medical community: anxious editorials have appeared in JAMA,17 the New
England Journal of Medicine,18 and the Annals of Internal Medicine.19
Were the statements by Alfred Caronia about Xyrem, and later by Amarin
about Vascepta, in fact “truthful and non-misleading”?
I. SOME BACKGROUND
The story of medicinal pills, powders, and potions is colorful, and
doubtless goes back to the beginning of human history. Sick people are
desperate and vulnerable, they want to be cured, many will try anything. In the
U.S., the market has always responded: in the nineteenth century, the wild west
13

Id. at *2.
Id. at *6.
15 See Monique C.M. Leahy, Off-Label Use of Prescription Medications § 1, 124 Am. Jur. Trials 487,
(2012) (stating that the off-label use of drugs approved by the FDA generally comports with the FDCA).
16 See Caronia, 703 F.3d at 166 (stating that “prohibiting off-label promotion by a pharmaceutical
manufacturer. . . interferes with the ability of physicians to receive potentially relevant treatment information”
and that “such barriers to information about off-label use could inhibit, to the public’s detriment, informed and
intelligent treatment decisions.”).
17 Joshua M. Sharfstein & Alta Charo, The Promotion of Medical Products in the 21st Century: Off-label
Marketing and First Amendment Concerns, JAMA (Nov. 3, 2015), http://jama.jamanetwork.com/article.aspx?
articleid=2442407&resultClick=1.
18 Jerry Avorn et al, Forbidden and Permitted Statements about Medications—Loosening the Rules, NEW
ENG. J. MED. (Sep. 3, 2015), http://www.nejm.org/doi/full/10.1056/NEJMhle1506365.
19 Jerry Avorn, In Opposition to Liberty: We Need a “Sovereign” to Govern Drug Claims, ANNALS OF
INTERNAL MEDICINE (Aug. 2015), http://annals.org/article.aspx?articleid=2375121&resultClick=1.
14
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was not just along the frontier. All kinds of concoctions were peddled as
miracle cures: this is when the term “snake oil” became a synonym for a
product fraudulently offered as a cure-all. Many of these drugs were
ineffective, some were dangerous: Mrs.Winslow’s Soothing Syrup, for
example, sold to comfort crying babies, was compounded with morphine.20
The first national law to protect consumers from such practices, the Pure
Food and Drug Act of 1906, required that the active ingredients of medicinal
compounds be listed on the label, and meet purity standards.21 Each major
subsequent revision of the law was passed in the wake of a preventable
tragedy.22
In 1937, to make a liquid preparation of the early antibiotic sulfanilamide,
Massengill, a pharmaceutical manufacturer, dissolved the chemical in the
solvent diethylene glycol. You might know a closely related compound,
ethylene glycol, a potent human toxin used today for antifreeze. Massengil
checked its product for appearance, taste and fragrance, but not for safety—
that was not required by the 1906 law.23 In short order, over 100 people died,
including 35 children.24 Congress quickly amended the law in 1938 to require
manufacturers to demonstrate the safety of their drugs to the FDA before they
could legally market them.25
In 1962, Congress tightened the FDCA again,26 this time in response to the
thalidomide disaster, which readers of a certain age will remember well:
thalidomide, a non-barbiturate sedative, was thought to be so safe it was
marketed over the counter in Europe to everyone, including pregnant women
for morning sickness. It was widely taken up. As the world found out to its
20 Mrs. Winslow’s Soothing Syrup, THE WOOD LIBRARY MUSEUM, http://www.woodlibrarymuseum.org/
museum/item/529/mrs.-winslow’s-soothing-syrup (last visited Feb. 6, 2016).
21 See Federal Food and Drugs Act of 1906: Regulatory Information, U.S. FOOD AND DRUG ADMIN.,
http://www.fda.gov/RegulatoryInformation/Legislation/ucm148690.htm (last updated May 20, 2009) (stating
the act was enacted by Senate and the House of Representatives).
22 Regulatory Information: Legislation, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/
RegulatoryInformation/Legislation/ (last updated July 7, 2015).
23 See Wood Library Museum, supra note 22 (detailing the requirements of the Federal Food and Drugs
Act of 1906).
24 Carol Ballentine, Taste of Raspberries, Taste of Death, The 1937 Elixir Sulfanilamide Incident,
FDA.GOV
(June
1981),
http://www.fda.gov/aboutfda/whatwedo/history/productregulation/
sulfanilamidedisaster/default.htm.
25 See supra Wood Library Museum, note 22.
26 Michelle Meadows, About FDA: Promoting Safe and Effective Drugs for 100 Years, FDA.GOV (Feb.
2006),
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/PromotingSafeandEffective
Drugsfor100Years/.
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horror, however, thalidomide is a potent teratogen: more than 10,000 children
were born with serious, often fatal, birth defects before the drug was taken off
the market. (A determined FDA officer, Francis Kelsey, kept it out of the
U.S.)27 Within the year, Congress amended the FDCA to require manufacturers
to demonstrate safety and effectiveness, based on adequate and well-controlled
clinical studies, conducted by qualified experts, to the FDA for each use for
which they planned to market a drug.28
Congress understood that just because a drug was safe and effective for one
condition did not mean it was safe and effective for a different one. To give a
notorious recent example, the FDA found a powerful anti-psychotic, Risperdal,
safe and effective for schizophrenia (its first indication), under certain
conditions for Bipolar I disorder, and for irritability associated with autistic
disorder.29 It is not, however, safe and effective for dementia-related psychosis,
even though it was widely marketed and prescribed for that purpose: patients
died.30 DOJ prosecuted Johnson & Johnson for illegal off-label marketing; the
FDA added a black box warning against this use to the label for Risperdal.31
Therefore, Congress designed the 1962 amendments—in particular, the
definition of a “new drug”—explicitly to prevent a sponsor from getting a new
drug on the market for an easy, narrow indication, then marketing it off-label
for wider, more lucrative, but more problematic, uses. Senator Kefauver, a
sponsor of the amendments, noted that if a manufacturer were not required to
demonstrate safety and effectiveness for each use, “the expectation would be
that the initial claims would be quite limited.” However, once the drug
received its initial approval, “the sky would be the limit and extreme claims of
any kind could be made. . .”32
II. MODERN MEDICINE
Starting in the years after World War II, and accelerating with passage of
Medicare, American medicine has undergone tremendous transformation and
27 Marilyn T. Miller & Kerstin K. Strömland, What can we learn from the thalidomide experience: an
ophthalmologic perspective, U.S. NAT’L LIBRARY OF MED. (July 17, 2013), http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3713624/.
28 Id.
29 Risperdal Black Box Warning, YOUR HEALTH ALERT, http://www.yourhealthalert.com/risperdal/blackbox-warning/.
30 Id.
31 Id.
32 S. Rep. No. 87-1774 (1962), as reprinted in 1962 U.S.C.C.A.N. 2884, 2901-2903.
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expansion. Scientists developed whole new classes of more powerful and
better targeted drugs, new laboratory tests and imaging equipment, more
detailed understanding of the physiology of health and disease down to the
molecular and genetic level. At the same time, scientists and physicians
developed appreciation for what has come to be called “evidence-based
medicine” and in particular, the importance of randomized, controlled clinical
trials (RCTs).
When a doctor prescribes a new medication for a very sick patient, and the
patient dies, the doctor has no way of knowing whether the patient died from
the disease or the medication—there is almost nothing in medicine that is
100%. If the patient recovers, it may be the effect of the medication, or the
condition resolved spontaneously, as many do. That’s why clinical trials need
decent numbers of subjects—and a control arm.
Far more often than we expected, treatments that seemed logical, intuitive
even, turned out to be ineffective, even dangerous. For example, physicians
assumed for many years that because premenopausal women suffered fewer
heart attacks than men of the same age (the women caught up after
menopause), female hormone replacement therapy would continue to protect
women after menopause. The Women’s Health Initiative, three randomized
controlled trials including more than 27,000 women, launched by the National
Institution of Health (NIH) in 1991, showed that it did not.33 In fact, the
women on replacement therapy slightly suffered more heart attacks, strokes
and breast cancer than the women who took nothing.34 Hormone replacement
therapy also failed to prevent Alzheimer’s disease or colon cancer.35 Earlier
clinical guidelines recommending hormone replacement for most women were
reversed within the year.
Conversely, as one Dr. Sinak noted, “The best way to improve the outcome
of a therapeutical trial is to leave out the controls.”36
Or, as another article put it:
Evidence-based medicine requires a critical appraisal of the literature
based upon study methodology and number of subjects. Not all
33

Questions and Answers about the WHI Postmenopausal Hormone Therapy Trials, WOMEN’S HEALTH
INITIATIVE (April 2004), https://www.nhlbi.nih.gov/whi/whi_faq.htm.
34 Id.
35 Id.
36 Ulrich Trohler, A Very Short History of Evidence Based Medicine, SLIDESHARE (April 2, 2008),
http://www.slideshare.net/Cochrane.Collaboration/troehler-symposium.
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references are equally robust. The findings of a large, prospective,
randomized and blinded trial should carry more weight than a case
37
report.

III. THE NEW BUSINESS MODEL
As American medicine became much better, it also became much bigger:
Health care now accounts for about 17% of U.S. Gross Domestic Product
(GDP).38 Pharmaceutical manufacturing in particular flourished, producing
thousands of new, powerful compounds: it is the most profitable sector in
health care. Since the 1990’s in particular, Wall Street has taken notice, and
financial considerations now drive the operation of the pharmaceutical
industry: the second largest corporate merger of all time is now planned
between two pharmaceutical manufacturers, Pfizer and Allergan, to create the
largest pharmaceutical company in the world. The deal is said to be worth
$160 billion.39
In particular, the business model of the pharmaceutical industry is now
geared to Wall Street expectations. Financiers demand huge and increasing
profits, blockbuster drugs, each and every year: they punish the stock of those
companies that don’t produce. Since the markets for individual diseases—other
than hypertension and high cholesterol—are rarely big enough to generate
Wall Street-scale profits, most of the pharmaceutical companies do exactly
what Senator Kefauver tried to prevent in 1962: they get a drug on the market
for one or two indications, based on legitimate, randomized controlled trials
scrutinized and approved by experts at the FDA—then aggressively market the
new drug off-label for other, more common diseases, based on, perhaps, some
small clinical trials without controls, “expert” opinion, a case report or two, or
maybe nothing at all, just as in the old days before 1962.
This is not just about hiring sales representatives like Alfred Caronia. The
large pharmaceutical manufacturers shape the ostensibly independent medical
reference literature that clinicians rely on: the pharmaceutical firms engage
international medical “communications companies”, like Excerpta Medica,
37 Christopher B. Willoughby, Complications Of Acute Coronary Syndromes: References, E.B.
MEDICINE (Dec. 29, 2015, 3:07 PM), http://www.ebmedicine.net/topics.php?paction=showTopicSeg&topic_
id=287&seg_id=5396.
38 Health expenditure, total (% of GDP), THE WORLD BANK, http://data.worldbank.org/indicator/SH.
XPD.TOTL.ZS (last visited Jan. 29, 2016).
39 Jackie Wattles & Heather Long, Pfizer and Allergan combine in Biggest Drug Merger Ever, CNN
MONEY (Nov, 23 2015), http://money.cnn.com/2015/11/23/investing/pfizer-allergan-merger/.
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which was owned by giant scientific publisher Elsevier, to design and develop
study protocols likely to produce favorable outcomes for the off-label uses, to
cherry-pick the data, write puff-pieces, pay co-operative academic authors, in
general, create market “buzz” as if they were selling smart phones. At the same
time, the manufacturers try to suppress unfavorable information, from clinical
trials and elsewhere.
In this way, they try to bootstrap their way onto the market. Once enough
physicians have prescribed their medication for the new use, the
pharmaceutical company will claim it is standard of care, it becomes difficult
to recruit patients for randomized trials, and it will take an independent body
like the NIH to prove, with a randomized controlled trial, that the drug is
actually ineffective or harmful.
Why is this a problem? A smart phone, or a faulty dishwasher, won’t kill a
customer: the wrong medication, prescribed to the wrong patient for the wrong
disease, just might, as thalidomide (and no doubt Mrs. Wright’s Soothing
Syrup, full of morphine) did in the past.
In a long form article in the Huffington Post, Steve Brill recounts how
Johnson & Johnson used all these techniques to market Risperdal, a potent
anti-psychotic designed to treat schizophrenia, to children for disruptive
behavior, and elderly demented people in nursing homes for agitation.40 The
company made billions of dollars, Wall Street cheered, but hundreds of
unknowing, non-schizophrenic patients suffered serious, irreversible adverse
side effects, including death.
IV. CARONIA AND AMARIN, REVISITED
I will leave to others the questions of whether corporations should have the
same right to free speech as ordinary mortals, and whether commercial
advertising should be protected like traditional political speech. However, the
Caronia41 and Amarin42 cases themselves demonstrate why it is important for
experts at the FDA to carefully regulate sales messages from pharmaceutical
manufacturers about their products, First Amendment “rights”
notwithstanding.

40 Steve Brill, America’s Most Admired Lawbreaker, HUFFINGTON POST: HIGHLINE, http://highline.
huffingtonpost.com/miracleindustry/americas-most-admired-lawbreaker/ (last visited Jan. 29, 2016).
41 Caronia, 703 F.3d at 149.
42 Amarin Pharma Inc., 2015 U.S. Dist. LEXIS 103944, at *2.
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Jazz Pharmaceutical followed the by now well-worn path to commercial
success. It succeeded in getting a limited indication for Xyrem from the FDA.
(In 2010, the agency turned down Jazz’s subsequent application for use in
fibromyalgia, based on some problems with its clinical trial and overwhelming
opposition—20 to 2—from the FDA outside Advisory Committee.)43 Jazz
hired sales reps and assigned them sales quotas that could not possibly be
satisfied in the on-label market: there were not enough patients in the sales
territories with narcolepsy with excessive daytime sleepiness or cataplexy.
So what does Mr. Caronia say about Xyrem? “It’s a very safe drug.”44 This,
despite the fact that GHB, the date-rape drug of which Xyrem is the sodium
salt, is classified by the U.S. Drug Enforcement Agency as Schedule 1, no
appropriate use, along with drugs like heroin.45 Xyrem is now legitimately on
the U.S. market, for narcolepsy, but safe? From the start, it has carried a black
box warning, the strongest warning the FDA can issue, reminding doctors and
patients that even at recommended doses, it can cause confusion, depression,
neuropsychiatric events, and respiratory depression.46 At higher doses,
especially in combination with alcohol, or dozens of other drugs, Xyrem can
cause seizures, coma and death.47 It is addictive: withdrawal symptoms can be
severe.48 It is so dangerous it can only be prescribed within a strict risk
management system.49 If Xyrem is safe, it is hard to imagine a drug the Second
Circuit would find dangerous. I doubt most people would consider “it’s a very
safe drug” a truthful and non-misleading statement.
Mr. Caronia goes on to suggest that Xyrem is useful for such common
conditions as Parkinson’s disease, even though these patients are generally on
a complicated regimen of other central nervous system (CNS) medications,
fibromyalgia, chronic pain, chronic fatigue syndrome, insomnia and weight
loss.50 But how do we know these assertions are truthful and non-misleading?
Evidence-based medicine tells us that scattered anecdotes provide no useful

43 Summary Minutes of the Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and
Risk Management Advisory Committee, FDA.GOV (Sept. 13, 2010), http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM227134.pdf.
44 Caronia, 703 F.3d at 157.
45 Drug Fact Sheet: GHB, DEA.GOV, http://www.dea.gov/druginfo/drug_data_sheets/GHB.pdf.
46 Id.
47 Id.
48 Id.
49 Xyrem Risk Management Program, FDA, http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/
21196lbl.pdf (last visited Jan. 29, 2016).
50 Caronia, 703 F.3d at 156.
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information about the safety or efficacy of a drug, yet it is not clear Caronia is
offering even these. Nowhere does the court mention a clinical trial, let alone a
RCT, supporting Caronia’s assertions. Yet the Second Circuit finds his
statements truthful and not-misleading—on the basis of nothing at all.
Judge Engelmayer in Amarin51 does only a little better. He believes the
FDA’s statement, “. . .the available evidence does not establish that reducing
triglycerides with a drug reduces the risk of cardiovascular events among
patients already treated with statins,” means that “‘the available evidence’ had
affirmatively established that reducing triglycerides with a drug does not
reduce cardiovascular risk in the relevant populations.”52 But, as Dr.
Sharfstein, a physician used to precision in analyzing clinical trial results,
pointed out in his Viewpoint article in JAMA, these two statements are not the
same.53
If ever there were cases demonstrating the importance judicial deference to
specialized Federal agency expertise, these are they.
As the late U.S. Senator Daniel Patrick Moynihan said, “Everyone is
entitled to his own opinions, but not to his own facts.”54
Most distressing, perhaps, is the heedless credulity with which these judges
swallow whole what can only be described as pharmaceutical industry
propaganda. Despite the well-documented history of tragedy from reckless
pharmaceutical marketing, from Mrs. Winslow’s Soothing Syrup to
antipsychotics such as Risperdal today, the courts don’t see a single problem.
Instead, Judge Engelmeyer confidently asserts that “. . .the therapeutic—indeed
sometimes life-saving—value of off-label uses of FDA-approved drugs has
been widely recognized.”55 In support of this sweeping statement, he offers—
nothing. He criticizes the FDA’s position that off-label marketing violates the
FDCA “[n]otwithstanding the potential benefits of off-label use of approved
drugs.”56 Again, no reference. Off-label prescribing due to off-label marketing
is an unalloyed good. Judge Engelmayer concurs with Amarin’s claim that

51

Amarin Pharma Inc., 2015 U.S. Dist. LEXIS 103944, at *57-58.
Id.
53 Joshua M. Sharfstein, supra note 19.
54 Daniel Patrick Moynihan Quotes: Quotable Quotes, GOODREADS, http://www.goodreads.com/quotes/
1745-everyone-is-entitled-to-his-own-opinion-but-not-to (last visited Jan. 29, 2015).
55 Amarin Pharma Inc., 2015 U.S. Dist. LEXIS 103944, at *10.
56 Id. at *9.
52
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“doctors desire. . .this information,”57 despite the fact that the very New
England Journal of Medicine article from which he takes his figure for offlabel use (21% of all prescriptions) disapproves of such common off-label
prescribing: “most off-label drug uses (73%) were shown to have little or no
scientific support. Atypical antipsychotics and antidepressants were
particularly likely to be used off-label without strong evidence. . .”.58 Indeed,
the author of the article, Randall Stafford M.D., Ph.D., is concerned that the
FDA has been unduly intimidated by the courts: he calls for stronger FDA
oversight of illegal off-label marketing.59 Dr. Stafford concludes:
I believe that the FDA must take an active role in fostering evidencebased practice, eliminating subversion of the approval process, and
requiring a balanced and fair presentation of scientific
evidence. . .The FDA might consider undertaking a range of new
activities in regulating off-label use, including. . . scrutinizing
marketing efforts to restrict materials on off-label uses that don’t
60
have strong support;” [emphasis added].

The First Amendment contemplates a vigorous marketplace of ideas and
opinions in which anyone can participate, from which the truth emerges.
However, today medicine is not such a marketplace: the pharmaceutical
industry has a disproportionate, well-financed and often highly biased voice,
driven by powerful, dangerous forces on Wall Street. Busy clinicians do not
have the time and expertise to carefully sort through unsupported
pharmaceutical claims, or even the access to proprietary information the FDA
can require manufacturers to provide: many of us, overwhelmed by the
avalanche of information, depend on the FDA to do heavy lifting for us, at
least in the first instance.
Whatever values the courts seek to advance in their “new First
Amendment” jurisprudence, in matters of medicine they would be wise to heed
instead the admonition of the ancient Greek physicians, “First do no harm.”

57

Id. at *12.
Randall S. Stafford, Regulating Off-Label Drug Use—Rethinking the Role of the FDA, 358 NEW ENG.
J. MED. 1427–29 (April 3, 2008), http://www.nejm.org/doi/full/10.1056/NEJMp0802107.
59 Id.
60 Id. (emphasis added).
58

